Friday, July 8, 2011
Exelixis Inc., of South San Francisco, said that it will report results from its Phase III trial of cabozantinib in medullary cancer (EXAM) by about three months. That provides additional time to reach the prespecified number of progression-free survival events for unblinding.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.